Literature DB >> 11425781

Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension.

N E Rhaleb1, H Peng, X P Yang, Y H Liu, D Mehta, E Ezan, O A Carretero.   

Abstract

BACKGROUND: N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP) is a natural inhibitor of pluripotent hematopoietic stem cell proliferation. Ac-SDKP plasma concentration is increased 5-fold after angiotensin-converting enzyme inhibition. Here we studied the effect of Ac-SDKP on monocyte/macrophage infiltration, fibroblast proliferation, and collagen deposition in the rat heart in renovascular hypertension. METHODS AND
RESULTS: We investigated whether long-term Ac-SDKP administration would prevent left ventricular (LV) hypertrophy and interstitial collagen deposition in rats with 2-kidney, 1-clip (2K-1C) hypertension. Ac-SDKP (400 microgram. kg(-1). d(-1)) did not affect development of hypertension. Mean blood pressure was similar in rats with 2K-1C hypertension whether they were given vehicle or Ac-SDKP and was higher than in controls. Both LV weight and cardiomyocyte size were significantly increased in rats with 2K-1C hypertension compared with controls and were unaffected by Ac-SDKP. Proliferating cell nuclear antigen- and monocyte/macrophage-positive cells were increased in the LV of 2K-1C hypertensive rats; this increase was significantly blunted by Ac-SDKP (P<0.001). LV interstitial collagen fraction was also increased in 2K-1C hypertensive rats given vehicle (10.1+/-0.8%) compared with sham (5.3+/-0.1%, P<0.0001), and this increase was prevented by Ac-SDKP (5.4+/-0.4%, P<0.001).
CONCLUSIONS: Ac-SDKP inhibited monocyte/macrophage infiltration, cell proliferation, and collagen deposition in the LV of hypertensive rats without affecting blood pressure or cardiac hypertrophy, suggesting that it may be partly responsible for the cardioprotective effect of angiotensin-converting enzyme inhibitors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11425781      PMCID: PMC4679287          DOI: 10.1161/01.cir.103.25.3136

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  40 in total

1.  Further studies on the biological activities of the CFU-S inhibitory tetrapeptide AcSDKP. I. The precise point of the cell cycle sensitive to AcSDKP. Studies on the effect of AcSDKP on GM-CFC and on the possible involvement of T-lymphocytes in AcSDKP response.

Authors:  J P Monpezat; E Frindel
Journal:  Exp Hematol       Date:  1989-12       Impact factor: 3.084

2.  Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.

Authors:  Y H Liu; X P Yang; V G Sharov; O Nass; H N Sabbah; E Peterson; O A Carretero
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

3.  Negative regulator of pluripotent hematopoietic stem cell proliferation in human white blood cells and plasma as analysed by enzyme immunoassay.

Authors:  P Pradelles; Y Frobert; C Créminon; E Liozon; A Massé; E Frindel
Journal:  Biochem Biophys Res Commun       Date:  1990-08-16       Impact factor: 3.575

4.  Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats.

Authors:  C Junot; L Nicolet; E Ezan; M F Gonzales; J Menard; M Azizi
Journal:  J Pharmacol Exp Ther       Date:  1999-12       Impact factor: 4.030

5.  Circadian-based effects of AcSDKP, with or without rhG-CSF on hematologic toxicity of chemotherapy in mice.

Authors:  X M Li; C Soulard; E Filipski; E Deschamps de Paillette; F Lévi
Journal:  Eur J Haematol       Date:  1998-03       Impact factor: 2.997

Review 6.  The effects of enalapril on blood pressure, renal hemodynamics, and renal function.

Authors:  M R Weir
Journal:  Clin Ther       Date:  1989 Sep-Oct       Impact factor: 3.393

7.  Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors.

Authors:  D Bonnet; F M Lemoine; S Pontvert-Delucq; C Baillou; A Najman; M Guigon
Journal:  Blood       Date:  1993-12-01       Impact factor: 22.113

8.  Angiotensin-converting enzyme and myocardial fibrosis in the rat receiving angiotensin II or aldosterone.

Authors:  Y Sun; A Ratajska; G Zhou; K T Weber
Journal:  J Lab Clin Med       Date:  1993-10

9.  Lisinopril, an angiotensin I-converting enzyme inhibitor, prevents entry of murine hematopoietic stem cells into the cell cycle after irradiation in vivo.

Authors:  A Rousseau-Plasse; J Wdzieczak-Bakala; M Lenfant; E Ezan; R Genet; S Robinson; T Briscoe; J Melville; A Riches
Journal:  Exp Hematol       Date:  1998-10       Impact factor: 3.084

10.  The tetrapeptide AcSerAspLysPro (Seraspenide), a hematopoietic inhibitor, may reduce the in vitro toxicity of 3'-azido-3'-deoxythymidine to human hematopoietic progenitors.

Authors:  C Grillon; D Bonnet; J Y Mary; M Lenfant; A Najman; M Guigon
Journal:  Stem Cells       Date:  1993-09       Impact factor: 6.277

View more
  35 in total

Review 1.  Protein NMR in biomedical research.

Authors:  W Jahnke; H Widmer
Journal:  Cell Mol Life Sci       Date:  2004-02-26       Impact factor: 9.261

2.  Intrapericardial procedures for cardiac regeneration by stem cells: need for minimal invasive access (AttachLifter) to the normal pericardial cavity.

Authors:  H Rupp; T P Rupp; P Alter; N Jung; S Pankuweit; B Maisch
Journal:  Herz       Date:  2010-10       Impact factor: 1.443

3.  N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research.

Authors:  Tang-Dong Liao; Xiao-Ping Yang; Martin D'Ambrosio; Yanlu Zhang; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2009-12-21       Impact factor: 10.190

Review 4.  The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis.

Authors:  Takako Nagai; Kyoko Nitta; Megumi Kanasaki; Daisuke Koya; Keizo Kanasaki
Journal:  Clin Exp Nephrol       Date:  2014-07-01       Impact factor: 2.801

5.  Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice.

Authors:  Nour-Eddine Rhaleb; Saraswati Pokharel; Umesh Sharma; Oscar A Carretero
Journal:  J Hypertens       Date:  2011-02       Impact factor: 4.844

6.  N-acetyl-seryl-aspartyl-lysyl-proline stimulates angiogenesis in vitro and in vivo.

Authors:  Dahai Wang; Oscar A Carretero; Xiao-Yi Yang; Nour-Eddine Rhaleb; Yun-He Liu; Tang-Dong Liao; Xiao-Ping Yang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-07-15       Impact factor: 4.733

7.  Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.

Authors:  Saman Rasoul; Oscar A Carretero; Hongmei Peng; Maria A Cavasin; Jialong Zhuo; Alicia Sanchez-Mendoza; David R Brigstock; Nour-Eddine Rhaleb
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

8.  Combination treatment with N-acetyl-seryl-aspartyl-lysyl-proline and tissue plasminogen activator provides potent neuroprotection in rats after stroke.

Authors:  Li Zhang; Michael Chopp; Hua Teng; Guangliang Ding; Quan Jiang; Xiao Ping Yang; Nour Eddine Rhaleb; Zheng Gang Zhang
Journal:  Stroke       Date:  2014-02-18       Impact factor: 7.914

9.  Role of N-acetyl-seryl-aspartyl-lysyl-proline in the antifibrotic and anti-inflammatory effects of the angiotensin-converting enzyme inhibitor captopril in hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; Tang-Dong Liao; Edward L Peterson; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2007-02-05       Impact factor: 10.190

10.  Renal protective effect of N-acetyl-seryl-aspartyl-lysyl-proline in dahl salt-sensitive rats.

Authors:  Morel E Worou; Tang-Dong Liao; Martin D'Ambrosio; Pablo Nakagawa; Branislava Janic; Edward L Peterson; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2015-10       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.